Klinik für diagnostische und interventionelle Radiologie und Neuroradiologie, MediClin Robert Janker Klinik, Villenstraße 8, 53129, Bonn, Germany.
Radiologe. 2020 Nov;60(Suppl 1):54-62. doi: 10.1007/s00117-020-00706-1.
Interventional therapies (IT) are increasingly popular treatment options for benign prostatic hyperplasia (BPH). IT aim to reduce morbidity and side effects related to invasive surgical procedures. To date, IT are considered experimental, though they are evolving rapidly and starting to challenge established surgical strategies. With gradually increasing evidence for the benefits of IT in BPH, several techniques are moving out of the realm of research and into everyday clinical practice. As such, IT provides encouraging mid-term functional outcomes with improved health-related quality of life (QoL), particularly in terms of better preservation of ejaculation. The distinct role IT could play as a bridge between exhausted drug-based treatment options and surgery is yet to be defined. Further studies are required before IT can be recommended as alternatives to invasive therapies. Systematic trials are needed to identify subgroups of patients who can benefit particularly from IT in comparison to other treatments, to identify features of the prostate particularly suited to a specific IT, and to analyze the durability of success for each technique.
介入治疗(IT)越来越受到良性前列腺增生(BPH)的欢迎。IT 旨在减少与侵入性手术相关的发病率和副作用。迄今为止,IT 被认为是实验性的,尽管它们发展迅速,开始挑战既定的手术策略。随着 IT 在 BPH 中益处的证据逐渐增加,一些技术正在从研究领域进入日常临床实践。因此,IT 提供了令人鼓舞的中期功能结果,并改善了健康相关生活质量(QoL),特别是在保留射精方面。IT 作为药物治疗和手术之间的桥梁可以发挥什么作用还有待确定。在 IT 可以被推荐作为侵入性治疗的替代方法之前,还需要进一步的研究。需要进行系统试验来确定可以从 IT 中特别受益的患者亚组,与其他治疗方法相比,以确定特别适合特定 IT 的前列腺特征,并分析每种技术成功的耐久性。